Skip to main
FBRX
FBRX logo

Forte Biosciences (FBRX) Stock Forecast & Price Target

Forte Biosciences (FBRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Forte Biosciences Inc. is advancing its product candidate, FB-102, through preclinical trials for various autoimmune conditions, indicating significant potential in untapped markets as treatment options for conditions like graft-versus-host disease, vitiligo, alopecia areata, and type 1 diabetes. The company has seen a notable increase in research and development expenses, reflecting a strong commitment to pushing forward its clinical and manufacturing activities, which is crucial for future growth. Additionally, the market success of competing treatments like PFE's Litfulo demonstrates the potential for FB-102 to gain substantial market share, particularly if it avoids adverse effects tied to existing therapies.

Bears say

Forte Biosciences faces significant challenges due to intense market competition from both established and emerging therapies, which could hinder its ability to effectively penetrate the market and achieve favorable pricing for its product candidate, FB-102. Furthermore, potential delays in clinical development, regulatory approvals, and commercialization timelines could lead to lengthier development periods, resulting in increased costs that may strain the company's financial resources. Additionally, the suboptimal performance of FB-102, as indicated by low placebo comparisons and inadequate study design, raises concerns about its efficacy and overall market viability compared to competitors.

Forte Biosciences (FBRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Forte Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Forte Biosciences (FBRX) Forecast

Analysts have given Forte Biosciences (FBRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Forte Biosciences (FBRX) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Forte Biosciences (FBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.